Phase 3 PhALLCON Trial Overview
Takeda recently announced results from the randomized, international, open‑label, multicenter Phase 3 PhALLCON trial, which evaluates the efficacy and safety of Iclusig (ponatinib) versus imatinib, both in combination with low‑intensity chemotherapy, as first‑line treatment in adult patients with newly diagnosed Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL).
Primary Endpoint Result
The Phase 3 PhALLCON trial met its primary endpoint. Compared with imatinib, Iclusig plus low‑intensity chemotherapy resulted in a higher rate of minimal residual disease (MRD)‑negative complete remission (CR) in adult patients with newly diagnosed Ph+ ALL. MRD negativity has been reported in the literature to be associated with improved long‑term patient outcomes.
Safety Profile
No new safety signals were observed during the trial. Trial data will be discussed with regulatory authorities and shared with the scientific community in the future.
Company Statement
“Ph+ ALL is an aggressive disease with no approved targeted first‑line therapy for patients in the U.S. There is a critical need for effective treatment that suppresses the development of difficult‑to‑treat mutations associated with poor long‑term outcomes,” said Dr. Awny Farajallah, Global Medical Affairs Oncology Lead at Takeda. “We are pleased to see how Iclusig addresses this gap in care for these patients and look forward to sharing the results.”
Mechanism of Action of Iclusig
Iclusig is a tyrosine kinase inhibitor (TKI) targeting BCR‑ABL1, an abnormal tyrosine kinase expressed in chronic myeloid leukemia (CML) and Ph+ ALL. Developed using a computational and structure‑based drug design platform, Iclusig is specifically designed to inhibit the activity of BCR‑ABL1 and its mutations. It inhibits native BCR‑ABL1 as well as all BCR‑ABL1 treatment‑resistant mutations, including the highly resistant T315I mutation.
Approved Indications for Iclusig
Iclusig received full FDA approval in November 2016 and is indicated for:
1.Adult patients with chronic‑phase CML (CP‑CML) who are resistant or intolerant to at least two prior kinase inhibitors.
2.Adult patients with accelerated‑phase (AP) or blast‑phase (BP) CML and adult patients with Ph+ ALL for whom no other kinase inhibitor is available.
3.Adult patients with T315I‑positive CML (CP, AP, or BP) or T315I‑positive Ph+ ALL.
Iclusig is not indicated or recommended for the treatment of newly diagnosed CP‑CML patients.
